Jason A. Mouabbi: 5 ILC Abstracts will be presented at ASCO24 as Poster Presentations on June 2nd
Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson Cancer Center, shared on X:
“5 ILC Abstracts will be presented at ASCO24 as Poster Presentations on Sunday, June 2nd at 9:00 AM – 12:00 PM.
1. Racial disparities in presentation and survival for lobular breast cancer
Presenter: Simran Sandhu (University of Galway, Ireland); David W. Lim
Data: SEER database study with 38,769 ILC patients
Findings: Black women present with more advanced disease; Asian women are younger at diagnosis. 5-year overall survival for Black women is worse.
Takeaway: We must bridge the gaps in care for ILC patients across different races.
2. The multiomic tumor microenvironment landscape of ILC
Presenter: Jason A. Mouabbi (MD Anderson Cancer Center), BostonGeneCorp
Data: MxIF on 2,139,084 cells from FFPE whole-slide tissues
Findings: Detailed multiomic analysis reveals 40% of ILC samples are immune enriched (potential for immunotherapy) and 30% are highly vascularized (potential for anti-angiogenesis therapy).
Takeaway: Many ILC patients may benefit from immunotherapy or anti-angiogenesis regimens.
3. Neoadjuvant targeted therapy in HER2-mutant lobular breast cancer
Presenter: Laura Kennedy (Vanderbilt-Ingram Cancer Center); Ariella Hanker, Carlos Arteaga
Background: 10% of ILCs have HER2 (ERBB2) mutations, linked to ET resistance and worse prognosis.
Study: NCT05919108, Phase II trial for 30 patients with Stage I-III ILC and HER2 mutation, receiving letrozole plus neratinib for 6 months pre-surgery.
4. Transcriptomic analysis of cAMP/PKA/CREB signaling in ILC
Presenter: Susrutha Puthanmadhom Narayanan (Washington University School of Medicine); Steffi Oesterreich
Data: RNA-seq from three large breast cancer databases
Findings: Up-regulation of cAMP/PKA/CREB signaling in ILC compared to NST/IDC.
Takeaway: Unique signaling pathway in ILC could lead to novel therapeutic targets.
5. Clinical-pathological characteristics and multigene assay risk scores in ILC
Presenter: Young-Won Lee (University of Ulsan College of Medicine, Seoul, Korea);
Data: Retrospective analysis of 238 ILC cases
Findings: Predictive factors for ODX recurrence score in ILC differ from IDC.
Takeaway: Need for ILC-specific risk prediction tools.”
Source: Jason A. Mouabbi/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023